high risk ofinfection to which such children are exposed. A policy of BCG vaccination at birth for the children of these ethnic groups born in this country, as recommended by the Department of Health and Social Security8 and the joint tuberculosis committee of the British Thoracic Society,9 would probably protect most immigrants' children. It is equally important to reduce the likelihood of exposure to infection by earlier diagnosis and prompt treatment of the index cases, as it is those with pulmonary tuberculosis positive on smear testing who are the main source of infection. Clearly, exposure to the risks of infection in the Indian subcontinent, which occurs when immigrants visit their country of origin or when their relatives visit this country, will contribute to the high level of infection in this ethnic group.
The white and Indian subcontinent patients also differed in the proportion of previously untreated patients with initial resistance to one or more antituberculosis drugs in 1983. The very low rates (16%) in both surveys for the white population reflect the high standards of chemotherapeutic practice over many years in the indigenous population of the United Kingdom. In contrast, 12 8% of the strains from the Indian subcontinent patients were resistant in 1983, a higher proportion than in 1978-9 (7-5%). Initial resistance was therefore more common in the Indian subcontinent patients in both surveys and had increased in the second, although in most cases resistance was to a single drug, usually streptomycin. Resistance to streptomycin alone, however, is probably of little clinical importance as use of this drug in primary chemotherapy has declined in the United Kingdom."
This report highlights the main findings of the survey but does not explore many important aspects in detail-for example, the non-respiratory lesions-and further reports are in preparation. Lesson of the Week Non-oliguric renal failure during treatment with mefenamic acid in elderly patients: a continuing problem ALI TAHA, RICHARD J LENTON, PETER S MURDOCH, NORMAN R PEDEN Mefenamic acid, a non-steroidal anti-inflammatory drug of the anthranilic acid group, is widely used for the relief of mild to moderate pain. Like other non-steroidal anti-inflammatory agents, mefenamic acid has been reported as having a range of nephrotoxic effects,' particularly in the elderly. None the less, the drug continues to be widely used at high dosage in elderly patients. We describe five patients referred to a geriatric medicine unit during one month with non-oliguric renal failure developing during treatment with mefenamic acid.
Mefenamic acid should be prescribed with great caution, if at all, to old people, particularly those receiving diuretics
Case histories
All patients were receiving mefenamic acid 500 mg three times a day. Tables I and II show their clinical and biochemical details. All the patients had developed diarrhoea and vomiting after beginning mefenamic acid, leading to depletion of fluid and electrolytes. Two patients (cases 1 and 2) had very poor oral intake of fluid, while four (cases 2-5) were also receiving diuretics, which were continued despite their deteriorating clinical state. In case 4 the serum potassium concentration at presentation was 8-1 mmol(mEq)/ 1. Discontinuation of mefenamic acid in all cases, and also the diuretic in cases 2-5, together with appropriate fluid replacement was associated with complete biochemical and clinical recovery in four patients. In case 4 the patient improved initially but died six weeks later from ischaemic heart disease. Postmortem examination showed changes in the kidneys compatible with chronic pyelonephritis and sustained hypertension, but no interstitial nephritis or papillary necrosis was noted.
Discussion
Non-steroidal anti-inflammatory agents inhibit the production of renal prostaglandins which appear to have important autoregulatory effects on renal blood flow, particularly in states where the plasma renin activity is increased, such as dehydration and diuretic treatment. Mefenamic acid commonly causes gastrointestinal disturbances,' which may include vomiting, diarrhoea, and even steatorrhoea.4 Gastrointestinal disturbances, particularly diarrhoea, occurred in all of our patients, and despite the manufacturer's Conversion: SI to traditionalunits-Urea: I mmol/1=60 mg, 100 ml. Creatinine: 1 [imol/l 0-0l mg 100 ml. Bicarbonate: 1 mmol/l-lmEq/1. recommendation in the data sheets the drug was not discontinued. We therefore believe that the gastrointestinal toxicity of mefenamic acid in our patients caused fluid and electrolyte depletion, sensitising the patients to the nephropathic effects of the drug mediated by inhibition of intrarenal prostaglandin synthesis. In addition, four of our patients were receiving diuretics, which may potentiate the nephropathic effects of the drug by contributing to extracellular fluid depletion. Two of the patients were receiving potassium conserving diuretics, and it has been suggested that triamterene in particular may predispose to the nephrotoxic effects of non-steroidal anti-inflammatory drugs.6 Concomitant diuretic treatment was also being given in several reported cases of mefenamic acid nephropathy. 8 Robertson et a12 considered that renal papillary necrosis was the potential mechanism of nephropathy induced by mefenamic acid, but in two patients renal biopsy disclosed interstitial nephritis. 9 Our fourth patient who had serious pre-existing renal disease showed neither of these renal conditions.
It is not clear whether the gastrointestinal and renal toxicity of mefenamic acid is dose related. In the absence of good evidence that the pharmacokinetics of mefenamic acid are unchanged in elderly subjects it seems wise to recommend the use of lower doses of this drug in old people. Another cause for concern is that our patients with vomiting and diarrhoea continued to receive mefenamic acid despite the manufacturer's recommendation to the contrary.5 It would seem prudent to advise any patient receiving the drug of the importance of gastrointestinal upset as a side effect and to warn the patient to discontinue treatment immediately should side effects develop.
It is also noteworthy that all of our patients were receiving mefenamic acid for conditions that would have been more appropriately treated by other methods. The prescription of mefenamic acid in all of these cases was an attempt to control symptoms only, without any effort being made to treat the primary disorder.
These five cases emphasise the dangers of using mefenamic acid in elderly patients. We conclude that if mefenamic acid is to be used at all as an analgesic in elderly subjects, then it must be used in the minimum effective dose, and that patients should be instructed to discontinue the drug should any evidence of gastrointestinal upset occur.
